Personalised treatments are lacking for MPM5, however recent insights into the inter-patient genomic heterogeneity of this cancer have revealed frequent somatic alterations involving the cancer genes BAP1, NF2 and CDKN2A6,7. This evidence concerns the gene BAP1 and cancer.